DUBLIN–(BUSINESS WIRE)–The “Global Sepsis Diagnostics Market: Analysis By Technology, Product, Method, Pathogen Type, Test Type, End-User, Region Size, Trends and Forecast up to 2029” report has been added to ResearchAndMarkets.com’s offering.
The global sepsis diagnostics market was valued at US$835.40 million in 2023. The market value is expected to reach US$1.39 billion by 2029. The market is expected to grow at a CAGR of approx. 9% during the forecasted period of 2024-2029.
Global sepsis diagnostics market is expected to continue its growth trajectory due to the sustained efforts to improve healthcare infrastructure, ongoing technological advancements, and increasing awareness about sepsis. The expanding adoption of point-of-care testing, particularly in remote and underserved areas, will further drive market growth by enabling timely diagnosis and treatment in settings with limited healthcare resources.
Additionally, the continued focus on research and innovation, coupled with strategic collaborations between healthcare providers, diagnostic companies, and research institutions, will contribute to the development of next-generation diagnostic tools, ensuring the market’s robust expansion in the years to come.
North America held the major share of the market. In the US, Government initiatives, such as the Sepsis Alliance and the Centers for Disease Control and Prevention’s (CDC) sepsis awareness programs, have significantly contributed to increasing awareness and early detection of sepsis.
Additionally, the National Sepsis Data Trust Initiative (NSDTI) is an independent, consensus-driven initiative that focuses on improving the diagnosis and treatment of sepsis patients and survivors through the creation of a National Sepsis Data Trust. Moreover, the US has a high incidence rate of sepsis, which necessitates the need for effective diagnostic solutions. For example, the CDC reports that over 1.7 million adults in America develop sepsis each year, with around 350,000 fatalities, underscoring the critical demand for efficient diagnostics.
Germany’s sepsis diagnostics market is thriving due to its advanced healthcare system, strong research and development capabilities, and significant government and institutional support. Germany has one of the highest healthcare expenditures in Europe, enabling extensive investment in cutting-edge diagnostic technologies.
The country’s focus on precision medicine and personalized healthcare solutions aligns well with the need for rapid and accurate sepsis diagnostics. Organizations like the German Sepsis Society (Deutsche Sepsis-Gesellschaft, DSG) play a crucial role in raising awareness and improving sepsis outcomes through education and advocacy.
Market Segmentation Analysis:
The microbiology segment held the highest share of the market, whereas the molecular diagnostics segment is expected to be the fastest-growing segment in the forecasted period. Microbiology remains a cornerstone in sepsis diagnostics due to its proven efficacy in identifying pathogens responsible for infections. The traditional blood culture method, despite being time-consuming, provides comprehensive data about bacterial strains and their antibiotic susceptibilities, which is crucial for tailoring specific treatments.
On the other hand, the demand for molecular diagnostics in sepsis has surged due to its ability to provide rapid and precise pathogen identification directly from clinical samples. Techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) enable the detection of bacterial, viral, and fungal DNA or RNA within a few hours, significantly faster than traditional culture methods. This rapid turnaround is crucial in the early stages of sepsis, where timely intervention can drastically improve patient outcomes.
The polymerase chain reaction segment held the highest share of the market, whereas the microarrays segment is expected to be the fastest-growing segment in the forecasted period. Microarrays are gaining popularity in the molecular sepsis diagnostics market due to their capability to analyze multiple genetic markers simultaneously, offering a high-throughput approach to pathogen identification and characterization. This technology involves hybridizing patient sample nucleic acids to a chip containing numerous probes, enabling the detection of a wide range of sepsis-related pathogens and resistance genes in a single test.
The blood culture media held the highest share of the market, whereas the software segment is expected to be the fastest-growing segment in the forecasted period. The demand for blood culture media in the global sepsis diagnostics market is rising due to its critical role in the initial detection and identification of pathogens responsible for sepsis. Blood culture media are essential for cultivating bacteria, fungi, and other microorganisms from blood samples, which is a fundamental step in diagnosing sepsis.
On the other hand, software is becoming increasingly important in the global sepsis diagnostics market due to its role in managing and analyzing complex diagnostic data. Advanced diagnostic software integrates with various diagnostic instruments and systems to streamline data collection, analysis, and reporting. This integration facilitates real-time monitoring of patient data, enabling healthcare providers to make timely and informed decisions.
Conventional diagnostics segment held the highest share of the market, whereas automated diagnostics segment is expected to be the fastest-growing segment in the forecasted period. The demand for automated diagnostics in the global sepsis diagnostics market is surging due to the need for efficiency, accuracy, and rapid turnaround in diagnosing sepsis.
Bacterial sepsis held the highest share of the market and is expected to be the fastest-growing segment in the forecasted period. Bacterial sepsis is a significant driver of growth in the global sepsis diagnostics market due to its high prevalence and severe impact on patient outcomes.
Laboratory tests held the highest share in the market, whereas point-of-care tests segment is expected to be the fastest-growing segment in the forecasted period. The demand for point-of-care (POC) tests are surging due to their ability to provide rapid, on-site results that are crucial for timely intervention in sepsis management. POC tests are designed to be used at or near the patient’s bedside, offering immediate diagnostic information that facilitates quick decision-making and treatment initiation. This is particularly important in critical care settings where every minute counts. Innovations in POC testing, such as portable molecular diagnostic devices and rapid immunoassays, have improved the accessibility and convenience of sepsis diagnostics.
Key Attributes:
Report Attribute
Details
No. of Pages
205
Forecast Period
2024 – 2029
Estimated Market Value (USD) in 2024
$0.9 Billion
Forecasted Market Value (USD) by 2029
$1.39 Billion
Compound Annual Growth Rate
9.0%
Regions Covered
Global
Market Dynamics
Growth Drivers
Aging Population
Rising Healthcare Expenditure
Growing Government Initiatives for Creating Sepsis Awareness
Increasing Incidence of Hospital-acquired Infections (HAIs)
Rising Number of Sepsis Cases
Increase in Funding and Support for Sepsis Diagnostics Research
Surging Collaboration and Partnerships
Regulatory Approvals and Reimbursement Policies
Challenges
High Cost of Automated Diagnostic Devices
Lack of Skilled Professionals
Market Trends
Development of Rapid Diagnostic Tests
Increasing Availability of Point-of-Care Diagnostic Tools
Integration of Artificial Intelligence (AI) and Machine Learning (ML)
Increasing Use of Biomarker-Based Diagnostics
Rising Technological Advancements in Sepsis Diagnosis
Integration of Electronic Health Records (EHR)
Global Market Analysis
Market: An Analysis
Market: An Overview
Market by Value
Market by Technology (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, and Others)
Market by Product (Blood Culture Media, Instruments, Assays & Reagents, and Software)
Market by Method (Conventional Diagnostics and Automated Diagnostics)
Market by Pathogen Type (Bacterial Sepsis, Fungal Sepsis, and Other Pathogen)
Market by Test Type (Laboratory Tests and Point-of-Care Tests)
Market by End-User (Hospitals, Pathology & Reference Laboratories, and Research Institutes and Others)
Market by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)
Market: Technology Analysis
Market by Technology: An Overview
Global Microbiology Sepsis Diagnostics Market by Value
Global Molecular Sepsis Diagnostics Market by Value
Global Molecular Sepsis Diagnostics Market by Type (Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, and Microarrays)
Global Molecular Sepsis Diagnostics Market Type by Value
Global Immunoassays Sepsis Diagnostics Market by Value
Global Flow Cytometry Sepsis Diagnostics Market by Value
Global Others Sepsis Diagnostics Market by Value
Market: Product Analysis
Market by Product: An Overview
Blood Culture Media Market by Value
Instruments Market by Value
Assays & Reagents Market by Value
Software Market by Value
Market: Method Analysis
Market by Method: An Overview
Global Conventional Sepsis Diagnostics Market by Value
Global Automated Sepsis Diagnostics Market by Value
Market: Pathogen Type Analysis
Market by Pathogen Type: An Overview
Global Bacterial Sepsis Diagnostics Market by Value
Global Fungal Sepsis Diagnostics Market by Value
Global Other Pathogen Sepsis Diagnostics Market by Value
Market: Test Type Analysis
Market by Test Type: An Overview
Global Laboratory Sepsis Diagnostics Tests Market by Value
Global Point-of-Care Sepsis Diagnostics Tests Market by Value
Market: End-User Analysis
Market by End-User: An Overview
Hospitals Market by Value
Pathology & Reference Laboratories Market by Value
Research Institutes and Others Market by Value
Company Profiles: Business Overview, Revenue by Technology and Application, Business Strategy
BioMerieux SA
Abbott Laboratories
Danaher Corporation (Beckman Coulter Inc.)
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Becton, Dickinson and Company
Koninklijke Philips NV
Siemens Healthineers AG
DiaSorin (Luminex Corporation)
Bruker Corporation
T2 Biosystems, Inc.
Immunexpress, Pty Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/jl47h3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
